Payment overview · 2025
General Payments
$34,645.80
82 reported records · 12 companies
Healthcare provider profile · identity verified
Sharad Sathyan, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · BLOOMFIELD, CT · NPI 1508065681
Verified facts
What the public records show
CMS Open Payments records show Sharad Sathyan, M.D received $34,645.80 in general payments during 2025 across 82 reported records.
Amgen Inc. accounted for 53.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Krystexxa, Lupkynis, Rayaldee, Veltassa.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Krystexxa by this doctor in 2024.
Aurinia Pharma U.S., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPKYNIS as an associated drug or biological on 7773 records involving 3649 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lupkynis by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rayaldee by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $18,583.71 | 53.6% | 31 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15,284.53 | 44.1% | 34 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.73 | 0.7% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$214.21 | 0.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $108.25 | 0.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.14 | 0.2% | 2 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $43.83 | 0.1% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $28.96 | 0.1% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $26.46 | 0.1% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $25.67 | 0.1% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $20.59 | 0.1% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.72 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,300.00 | 9 |
| Consulting Fee | $11,400.00 | 6 |
| Travel and Lodging | $4,315.47 | 15 |
| Food and Beverage | $2,100.40 | 44 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,500.00 | 2 |
| Education | $29.93 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18,583.71 | 31 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $9,463.15 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $204.97 | 4 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $141.36 | 1 | 2025 |
Source payment records
|
|||||
| ELLIPSYS VASCULAR ACCESS SYSTEM Normalized: ellipsys vascular access system |
Device | Medtronic, Inc. | $72.85 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $43.83 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $34.34 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $34.34 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUPKYNIS lupkynis |
2025 | Lupkynis | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Aurinia Pharma U.S., Inc. Exact reporting entity; no affiliate inference |
2025 | LUPKYNIS open payments reported associated product |
CMS Open Payments — General Payments 7773 supporting records · 3649 recipient NPIs · example record 1249402448 |
Lupkynis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 261 | 83 |
| Losartan Potassium | Losartan Potassium | 244 | 84 |
| Calcitriol | Calcitriol | 211 | 67 |
| Lisinopril | Lisinopril | 184 | 65 |
| Farxiga | Dapagliflozin Propanediol | 182 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 50 |
| Kerendia | Finerenone | 109 | 21 |
| Torsemide | Torsemide | 96 | 37 |
| Jardiance | Empagliflozin | 93 | 28 |
| Chlorthalidone | Chlorthalidone | 67 | 22 |
| Allopurinol | Allopurinol | 63 | 18 |
| Valsartan | Valsartan | 58 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 54 | 21 |
| Carvedilol | Carvedilol | 44 | 17 |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | 14 |
| Veltassa | Patiromer Calcium Sorbitex | 39 | suppressed |
| Calcium Acetate | Calcium Acetate | 38 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 12 |
| Velphoro | Sucroferric Oxyhydroxide | 34 | 13 |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Prosol | Parenteral Amino Acid 20% No.1 | 26 | suppressed |
| Rayaldee | Calcifediol | 26 | suppressed |
| Auryxia | Ferric Citrate | 23 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 22 | suppressed |
| Krystexxa | Pegloticase | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Lupkynis | Voclosporin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34,645.80 · 82 records | Amgen Inc. | ELLIPSYS VASCULAR ACCESS SYSTEM, Fabhalta, Filspari, KRYSTEXXA, LUPKYNIS, Ozempic, RAYALDEE, SYMPLICITY G3, TARPEYO, TERLIVAZ, Vanrafia, Veltassa, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Krystexxa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error